Fulgent GeneticsMEX:FLGT 64 Beneish M-Score is -2.64 as of Jun. 25, 2026. GuruFocus rates MEX:FLGT with a GF Score™ of 64/100 and a GF Value™ of MXN729.64 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Fulgent Genetics ranks better than 54.87% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -2.64 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for Fulgent Genetics's Beneish M-Score or its related term are showing as below:
MEX:FLGT'
s Beneish M-Score Range Over the Past 10 Years
Min: -3.63 Med: -2.42 Max: 33.66
Current: -2.64
During the past 12 years, the highest Beneish M-Score of Fulgent Genetics was 33.66. The lowest was -3.63. And the median was -2.42.
Fulgent Genetics Beneish M-Score Related Terms
Fulgent Genetics Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Fulgent Genetics's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:FLGT vs CSTL, MYGN, PRE: Beneish M-Score Comparison
For the Diagnostics & Research subindustry, Fulgent Genetics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics Beneish M-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Fulgent Genetics for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 0.8215
+
0.528 * 1.0025
+
0.404 * 0.8578
+
0.892 * 1.0102
+
0.115 * 1.0301
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 1.1847
+
4.679 * 0.023069
-
0.327 * 1.4183
=
-2.75
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(479.521 / (479.521 + 2190.603))
/
(443.001 / (443.001 + 2097.996))
=
0.179588
/
0.174341
=
1.0301
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-1347.5 - -185.152
-
-1643.388)
/
20852.455
=
0.023069
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Fulgent Genetics has a M-score of -2.75 suggests that the company is unlikely to be a manipulator.
Fulgent Genetics (MEX:FLGT) has a Beneish M-Score of -2.64 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Fulgent Genetics and its competitors. According to the industry distribution chart, Fulgent Genetics ranks #88 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 45.1%.
Is Fulgent Genetics' Beneish M-Score too high?
Fulgent Genetics' current Beneish M-Score is -2.64. Based on the distribution chart, Fulgent Genetics ranks #88 out of 195 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Fulgent Genetics has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' Beneish M-Score compare to CSTL and MYGN?
According to the Medical Diagnostics & Research industry distribution chart, Fulgent Genetics ranks #88 out of 195 companies for Beneish M-Score. This puts Fulgent Genetics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Diagnostics & Research company?
A good Beneish M-Score depends on the Medical Diagnostics & Research industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Fulgent Genetics and its competitors. Fulgent Genetics's current Beneish M-Score is -2.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (MEX:FLGT) is currently considered Possible Value Trap. The stock's GF Value™ is MXN729.64, compared to a current price of MXN312.50 — trading 57.2% below its estimated fair value. The current Beneish M-Score is -2.64. Fulgent Genetics' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Fulgent Genetics (MEX:FLGT), the current Beneish M-Score is -2.64 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulgent Genetics (MEX:FLGT) Overvalued in 2026?
Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued.
The current stock price of MXN312.50 is trading 57.2% below its estimated GF Value™ of MXN729.64.
GuruFocus considers Fulgent Genetics to be Possible Value Trap.
Key valuation signals for MEX:FLGT:
Beneish M-Score: -2.64
GF Value™: MXN729.64 vs. price of MXN312.50 (57.2% below fair value)
No single metric tells the full story. See the MEX:FLGT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
64GF Score
Get the complete analysis for MEX:FLGT
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:FLGT has been successfully added to your 
